Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-1360
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
S-1360 (also known as GW810781) is a small molecule HIV integrase inhibitor that was developed by GlaxoSmithKline for the treatment of HIV infection. It was evaluated in Phase II clinical trials to assess its antiviral effect, safety, tolerability, and pharmacokinetics in HIV-infected patients. The drug demonstrated acceptable pharmacokinetic profiles and tolerability but its development was discontinued in July 2003. Its mechanism of action involves inhibition of the human immunodeficiency virus integrase enzyme (HIV IN), which is essential for viral DNA integration into the host genome[1][2][3][4][5][7].
- Other names
- GW810781GW-810781GW 810781S-1360S1360S 1360
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on S-1360.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-1360.